公开(公告)号：US20170159114A1

公开(公告)日：2017-06-08

申请号：US15215426

申请日：2016-07-20

Applicant: GENENTECH, INC.

Inventor： Robert Graham ,  Timothy W. Behrens ,  Tsontcho Ianchulev ,  Howard Shapiro

IPC: C12Q1/68 ,  C07K16/22

CPC classification number: C12Q1/6846 ,  C07K16/22 ,  C12Q1/6883 ,  C12Q2531/113 ,  C12Q2531/137 ,  C12Q2600/106 ,  C12Q2600/156

Abstract: Methods for determining whether a patient is at increased risk of developing wet AMD or whether a patient has an increased likelihood of benefiting from treatment with a high-affinity anti-VEGF antibody.

公开(公告)号：US10053734B2

公开(公告)日：2018-08-21

申请号：US15040949

申请日：2016-02-10

Applicant: Genentech, Inc.

Inventor： Timothy W. Behrens ,  Robert R. Graham

IPC: C12Q1/6883

CPC classification number: C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/156

Abstract: Methods of identifying, diagnosing, and prognosing lupus, including certain subphenotypes of lupus, are provided, as well as methods of treating lupus, including certain subpopulations of patients. The methods provided are based on a set of alleles associated with systemic lupus erythematosus (SLE) risk loci including BLK, TNIP1, PRDM1, JAZF1, UHRF1BP1, IL10, IFIH1, CFB, CEC16A, IL12B and SH2B3 that contribute to SLE risk. Also provided are methods for identifying effective lupus therapeutic agents and predicting responsiveness to lupus therapeutic agents.

公开(公告)号：US20140286947A1

公开(公告)日：2014-09-25

申请号：US13999496

申请日：2014-03-04

Applicant: Genentech, Inc.

Inventor： Timothy W. Behrens ,  Robert Royal Graham

IPC: C12Q1/68

CPC classification number: C12Q1/6827 ,  C12Q1/6883 ,  C12Q2600/156

Abstract: The present invention relates to methods for identifying individuals with intermediate age-related macular degeneration (AMD) who possess a greater risk of progression to advanced AMD, using a polygenic score calculated based on the results of genome-wide gene association studies, using thousands of single-nucleotide polymorphisms (SNPs).

Abstract translation: 本发明涉及使用基于全基因组的基因关联研究的结果计算的多基因评分，使用数千种以上的基因组全基因关联研究，鉴定具有中度年龄相关性黄斑变性（AMD）的个体，其具有进展为高级AMD的更大风险 单核苷酸多态性（SNP）。

公开(公告)号：US20140154247A1

公开(公告)日：2014-06-05

申请号：US13974817

申请日：2013-08-23

Applicant: Genentech, Inc.

Inventor： Timothy W. Behrens ,  Kasia Owczarczyk ,  Michael J. Townsend

IPC: C12Q1/68

CPC classification number: C12Q1/6883 ,  A61K38/00 ,  C07K14/70521 ,  C07K2319/30 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  C12Q2600/16

Abstract: Biological markers that predict patient responsiveness to B-cell antagonists are provided. Also provided are methods of using such biological markers. In addition, methods for identifying patients suffering from an autoimmune disease, e.g., rheumatoid arthritis, who are not likely to respond to B-cell antagonists are provided, as are methods of treating such patients. Methods for selecting therapeutic agents to treat such patients are also provided.

Abstract translation: 提供了预测患者对B细胞拮抗剂的反应性的生物标志物。 还提供了使用这种生物标记物的方法。 此外，提供了用于鉴定患有自身免疫性疾病例如类风湿性关节炎的患者的方法，所述患者不太可能对B细胞拮抗剂作出反应，以及治疗这些患者的方法。 还提供了用于选择治疗这些患者的治疗剂的方法。

公开(公告)号：US20180163262A1

公开(公告)日：2018-06-14

申请号：US15653460

申请日：2017-07-18

Applicant: Genentech, Inc.

Inventor： Timothy W. Behrens ,  Robert Royal Graham

IPC: C12Q1/6827 ,  C12Q1/6883

CPC classification number: C12Q1/6827 ,  C12Q1/6883 ,  C12Q2600/156

Abstract: The present invention relates to methods for identifying individuals with intermediate age-related macular degeneration (AMD) who possess a greater risk of progression to advanced AMD, using a polygenic score calculated based on the results of genome-wide gene association studies, using thousands of single-nucleotide polymorphisms (SNPs).

公开(公告)号：US09982302B2

公开(公告)日：2018-05-29

申请号：US15019615

申请日：2016-02-09

Applicant: Genentech, Inc.

Inventor： Timothy W. Behrens ,  Kasia Owczarczyk ,  Michael J. Townsend

IPC: C12Q1/68 ,  C07K14/705 ,  A61K38/00

CPC classification number: C12Q1/6883 ,  A61K38/00 ,  C07K14/70521 ,  C07K2319/30 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  C12Q2600/16

Abstract: Biological markers that predict patient responsiveness to B-cell antagonists are provided. Also provided are methods of using such biological markers. In addition, methods for identifying patients suffering from an autoimmune disease, e.g., rheumatoid arthritis, who are not likely to respond to B-cell antagonists are provided, as are methods of treating such patients. Methods for selecting therapeutic agents to treat such patients are also provided.

公开(公告)号：US20140037618A1

公开(公告)日：2014-02-06

申请号：US13902714

申请日：2013-05-24

Applicant: GENENTECH, INC.

Inventor： Svetlana Pidasheva ,  Hilary Clark ,  Nico P. Ghilardi ,  Timothy W. Behrens ,  Hergen Spits ,  Sara Trifari

IPC: G01N33/68 ,  C12Q1/68

CPC classification number: G01N33/6872 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/156

Abstract: The present invention relates to compositions and methods of diagnosing and treating autoimmune and inflammatory disorders that are characterized by IL-23R loss-of-function mutations.

Abstract translation: 本发明涉及以IL-23R功能丧失突变为特征的诊断和治疗自身免疫性和炎症性疾病的组合物和方法。